Chromium urine levels can be used to monitor short term exposure. The form of chromium greatly influences distribution. Trivalent chromium resides in the plasma and is usually not of clinical importance. Hexavalent chromium is considered highly toxic. Symptoms associated with chromium toxicity vary based upon route of exposure and dose and may include dermatitis, impairment of pulmonary function, gastroenteritis, hepatic necrosis, bleeding, and acute tubular necrosis.
The ACGIH Biological Exposure Index for daily exposure of hexavalent chromium is an increase of 10 µg/gCRT between pre-shift and post-shift urine collections. The ACGIH Biological Exposure Index for long-and short-term hexavalent chromium is an end-of-shift concentration of 30 µg/gCRT at the end of the work week.
See Compliance Statement B
Statement B: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.